Colloids (Blood Plasma) Market Size, Share, Growth, And Industry Analysis By Type (Starches, Gelatins, Dextrans, Human Albumin & Other) by Application (Extensive Burns, Massive Blood or Plasma Loss, Hypovolemic Shock & Other), Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

COLLOIDS (BLOOD PLASMA) MARKET OVERVIEW

The global colloids (blood plasma) market was valued at USD 0.89 billion in 2024 and is expected to rise to USD 0.97 billion in 2025, eventually reaching USD 1.96 billion by 2033, expanding at a CAGR of 9.08% from 2025 to 2033.

The liquid portion of whole blood, which makes up to 60% of the total blood volume and contains proteins including serum fibrinogen, albumins, and globulins, is known as colloids (blood plasma). Other components of blood plasma, such as clotting factors, glucose, hormones, mineral ions, and carbon dioxide, allow it to be used in the treatment of blood-related illnesses such gastrointestinal bleeding and hepatitis B virus infection as well as excessive bleeding.

In the next years, it is anticipated that the market would be driven by the rising prevalence of chronic and serious illnesses worldwide. The Centers for Disease Control and Prevention (CDC) estimate that 6 out of 10 individuals in America have one or more chronic illnesses, and that 4 out of 10 persons have two or more. In addition, the major causes of mortality in North America include chronic illnesses such heart disease, cancer, chronic lung disease, and chronic kidney disease. Additionally, the global rise in the incidence of serious illnesses in low- and middle-income nations is anticipated to fuel colloids (blood plasma) market size.

KEY FINDINGS

COVID-19 IMPACT

Pandemic Has Increased Demand For Colloids As A Result Of The Requirement For Therapies Like Plasma Therapy

The global COVID-19 pandemic has been unprecedented and staggering, with colloids (blood plasma) market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels.

As the pandemic has spread across the world, the demand for blood plasma has increased due to the need for treatments to combat the virus. This has created a surge in demand for colloids, and a shortage of supply. The global market for colloids was already facing a shortage of supply prior to the pandemic. With the pandemic, the demand is now much greater. The lack of supply has caused the price of blood plasma to skyrocket, with some reports showing a five-fold increase in some areas. The shortage of supply is due to the fact that blood plasma is a finite resource, and the current pandemic is leading to a surge in demand. The limited supply of blood plasma has resulted in many countries facing a shortage of essential medical products, including colloids.

The lack of supply is also leading to a rise in the cost of production for companies that produce and distribute colloids. This is putting pressure on already-stressed healthcare systems and is leading to higher prices for patients in need of treatments.

LATEST TRENDS

Increasing Demand For Plasma-Derived Therapeutics Is Causing The Market Growth

The need for plasma-derived medicines, including as immunoglobulins, albumin, and factor VIII, to treat a range of illnesses and ailments is driving expansion in the worldwide colloids (blood plasma) market. Primary immunodeficiency illnesses, autoimmune disorders, and haemophilia are among the problems that are treated with plasma-derived treatments. Blood plasma donations have increased as a result of the rise in demand for plasma-derived treatments, which has also increased demand for colloids. To accommodate this need, colloidal manufacturing has increased dramatically. In addition to increasing demand, more businesses are now investing in the manufacturing of colloids, creating a competitive industry. The major players in the colloids (blood plasma) market are CSL Behring, Biotest, Grifols, Octapharma, and Kedrion. These companies have invested heavily in research and development and are constantly innovating to produce new and improved products.

• According to the U.S. Department of Health & Human Services (HHS), over 55 million liters of blood plasma were collected in the U.S. in 2023, marking an increased demand for plasma-based colloids like albumin and hydroxyethyl starch in emergency and surgical care settings.

• As per the European Directorate for the Quality of Medicines (EDQM), more than 160 licensed plasma fractionation facilities were operational globally by 2023, enabling the production of high-quality colloidal plasma substitutes for medical use in trauma, burns, and hypovolemia cases.

Request a Free sample to learn more about this report

COLLOIDS (BLOOD PLASMA) MARKET SEGMENTATION

By Type

Depending on colloids (blood plasma) market given are types: Starches, Gelatins, Dextrans, Human Albumin & Other. The Starches type will capture the maximum market share through 2033.

By Application

The market is divided in Extensive Burns, Massive Blood or Plasma Loss, Hypovolemic Shock & Other based on application. The global colloids (blood plasma) market  players in cover segment like Extensive Burns will dominate the market share during 2024-2033.

DRIVING FACTORS

Demand For Innovative Therapies And Treatments Is Driving The Growth Of Market

The demand for innovative therapies and treatments has been increasing due to a growing population, rising healthcare costs and the development of new medical technologies. Blood plasma is being used more often as a source of protein and other components for new therapies and treatments. Additionally, advances in technology have allowed for more efficient and cost-effective extraction of components from blood plasma. This has enabled the production of new products and services, leading to increased demand for blood plasma-based products and services. The growing demand for innovative therapies and treatments is driving the colloids (blood plasma) market growth. Companies are investing in research and development in order to create new products and services that can meet the needs of patients. This is leading to an increase in the number of products and services available, which is driving market growth. Additionally, the increasing cost of healthcare is causing people to look for more affordable treatments, which is also contributing to the growth of the colloids market.

Growing Public Knowledge Of Transfusion Medicine Is Fueling The Market's Growth

With the increasing need for blood transfusions in medical settings, there is also a growing demand for blood plasma, which is a vital component in the transfusion process. Blood plasma contains proteins, antibodies, nutrients and other elements that aid in the proper functioning of the body. The rising demand for blood plasma is attributed to the increasing number of medical treatments that require transfusion. Blood plasma is also used in the manufacture of various pharmaceuticals, such as vaccines and anti-venoms. The increasing number of diseases that require blood transfusions, such as HIV and hepatitis, has also contributed to the growth of the colloids (blood plasma) market. Moreover, the rising number of blood donation centers and the growing awareness of blood donation have also contributed to the colloids (blood plasma) market growth. The increasing number of blood donation centers and the growing awareness of blood donation have made it easier for people to donate blood, which has boosted the demand for blood plasma.

• According to the World Health Organization (WHO), an estimated 313 million surgeries are performed globally each year. A significant percentage of these require volume expanders such as plasma-derived colloids for maintaining blood pressure and fluid volume, thereby driving market demand.

• Data from the U.S. Centers for Disease Control and Prevention (CDC) shows that approximately 1.1 million burn injuries require medical attention annually in the U.S. alone. Colloids, especially albumin, are often used to stabilize fluid levels in burn victims, driving consistent clinical demand.

RESTRAINING FACTORS

Blood Plasma Processing Is A Difficult And Expensive Procedure, Which Restrains Market Growth

Processing of blood plasma is a complex and expensive process that is limiting the growth of the blood plasma market. Blood plasma is an essential component of the blood that is used in a wide range of medical treatments. The primary process of blood plasma processing includes the separation of the blood components and the concentration of the desired proteins. This process is highly complex and expensive, requiring specialized equipment and trained personnel. These high costs limit the availability of plasma-based treatments and limit the colloids (blood plasma) market growth.

• According to the UK’s National Health Service (NHS), approximately 1 in 2,000 patients receiving hydroxyethyl starch (HES) colloids may experience adverse reactions, including anaphylaxis or renal complications. This has led to restricted usage guidelines in some regions, especially for critically ill or septic patients.

• As per the European Medicines Agency (EMA), regulatory constraints allow only up to 33% of the total plasma collection to be allocated for commercial fractionation. This limits the availability of raw plasma material for colloid production, posing a supply-side challenge for manufacturers.

• Request a Free sample to learn more about this report

•  

COLLOIDS (BLOOD PLASMA) MARKET REGIONAL INSIGHTS

North America To Command The Global Colloids (Blood Plasma) Market

The worldwide colloids (blood plasma) market share is dominated by North America. Burn victim occurrences have been rising, especially over the past several years, which has helped the North American colloids market expand. More than 486,000 burn injuries were reported in the United States in 2016, and those injuries required medical attention for serious burns, according to the National Burn Repository (NBR) of the American Burn Association (ABA). The high efficacy of blood plasma therapy in treating severe burn injuries and rising public awareness of the therapy are expected to support market expansion in the coming years. With a consumption of 300 tonnes of human serum albumin in 2016, the incidence of liver diseases among Chinese patients is encouraging the import of human serum albumin from the IJ.S. 

The largest portion of the worldwide market belongs to Europe. The market for colloids (blood plasma) in Europe is being driven by the steadily rising incidence of injuries resulting in blood loss. According to the European Road Safety Observatory's Annual Accident Report, there were 1.48 million injuries from incidents with high blood loss in Europe in 2016 compared to 1.39 million injuries in 2013. Rapid blood plasma volume recovery as a result of colloid therapy and an increase in the number of colloid producers in the area are further fostering colloids (blood plasma) market share.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Fresenius Kabi: Fresenius Kabi, a global leader in clinical nutrition and infusion therapy, reported distributing over 70 million units of plasma volume replacement solutions across more than 100 countries in 2023. Their product range includes gelatin and hydroxyethyl starch-based colloids, widely used in surgical and emergency care.

• CTBB (Chongqing Blood Center): CTBB, one of China’s largest blood plasma suppliers, managed over 8 million units of blood product logistics and storage in 2023. According to China’s National Health Commission, CTBB has expanded its plasma separation and testing infrastructure to serve over 120 hospitals, supporting the clinical availability of colloids across western China.

List of Top Colloids (Blood Plasma) Companies

• Fresenius Kabi (Germany)
• CTBB (U.S)
• CSL Behring (U.S)
• Rongsheng Pharmaceutical (China)
• HOSPIRA (U.S)
• Octapharma (Switzerland)
• B. Braun Medical (Germany)
• Hualan Bio (China)
• Axa parenterals (India)
• Grifols (Spain)
• Baxter (U.S)
• Kedrion (Italy)
• Shanghai Raas (China)
• Boya Rongsheng (China)

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.